Flanvotumab（Cat No.:I042100）is an investigational monoclonal antibody that targets the immune checkpoint receptor TIGIT (T-cell immunoreceptor with Ig and ITIM domains), which is involved in suppressing immune responses, particularly in the tumor microenvironment. By inhibiting TIGIT, flanvotumab aims to enhance T-cell activation and promote stronger anti-tumor immunity. It is being studied in clinical trials for various cancers, including non-small cell lung cancer (NSCLC) and melanoma, to evaluate its potential in improving immune responses against tumors. Its safety, efficacy, and potential role in combination therapies are key areas of investigation.
